Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis - PubMed
3 hours ago
- #hormone therapy
- #radiotherapy
- #prostate cancer
- Hormone therapy's impact on overall survival with postoperative radiotherapy (PORT) for recurrent prostate cancer was analyzed.
- Individual patient data (IPD) meta-analysis of six randomized trials involving 6057 patients with a median follow-up of 9.0 years.
- Adding hormone therapy to PORT did not significantly improve overall survival (HR 0.87, 95% CI 0.76-1.01, p=0.06).
- No significant interaction found between hormone therapy duration and survival benefit (pinteraction=0.17).
- Significant interaction observed with pre-PORT PSA levels >0.5 ng/mL vs ≤0.5 ng/mL (pinteraction=0.02).
- For PSA ≤0.5 ng/mL, no meaningful survival benefit from adding hormone therapy (short-term or long-term) to PORT.
- Upper bounds of 95% CI for overall survival HR crossed 1.0 for short-term hormone therapy across all PSA levels.
- For long-term hormone therapy, upper bounds of 95% CI fell below 1.0 at PSA >1.6 ng/mL.
- Need for biomarkers to predict potential hormone therapy benefit identified as an unmet need.
- Funding provided by the National Institutes of Health.